Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Coch

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
International Journal of Cancer|June 5, 2014
HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancerOliver Zivanovic, Alina Abramian, Maximilian Kullmann, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Immunity|April 16, 2020
Immune Sensing of Synthetic, Bacterial, and Protozoan RNA by Toll-like Receptor 8 Requires Coordinated Processing by RNase T2 and RNase 2Thomas Ostendorf, Thomas Zillinger, Katarzyna Andryka, et al.
Cell Reports. Medicine|September 1, 2023
Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapySimon Heidegger, Florian Stritzke, Sarah Dahl, et al.
The EMBO Journal|November 1, 2011
Expression of type I interferon by splenic macrophages suppresses adaptive immunity during sepsisTimo Schwandt, Beatrix Schumak, Gerrit H Gielen, et al.
The Journal of Clinical Investigation|May 20, 2020
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyLina Such, Fang Zhao, Derek Liu, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|April 1, 2022
Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage (FINISHER) trial: Study protocol for a randomized controlled trialErdem Güresir, Tim Lampmann, Sylvia Bele, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
International Journal of Cancer|June 5, 2014
HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancerOliver Zivanovic, Alina Abramian, Maximilian Kullmann, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Immunity|April 16, 2020
Immune Sensing of Synthetic, Bacterial, and Protozoan RNA by Toll-like Receptor 8 Requires Coordinated Processing by RNase T2 and RNase 2Thomas Ostendorf, Thomas Zillinger, Katarzyna Andryka, et al.
Cell Reports. Medicine|September 1, 2023
Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapySimon Heidegger, Florian Stritzke, Sarah Dahl, et al.
The EMBO Journal|November 1, 2011
Expression of type I interferon by splenic macrophages suppresses adaptive immunity during sepsisTimo Schwandt, Beatrix Schumak, Gerrit H Gielen, et al.
The Journal of Clinical Investigation|May 20, 2020
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyLina Such, Fang Zhao, Derek Liu, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|April 1, 2022
Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage (FINISHER) trial: Study protocol for a randomized controlled trialErdem Güresir, Tim Lampmann, Sylvia Bele, et al.
Lancet (London, England)|February 21, 2019
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Theophilos Tzaridis, Frederic Mack, et al.
Pageof 7